Replimune Group (NASDAQ:REPL) CEO Sushil Patel Sells 10,000 Shares

Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $11.13, for a total transaction of $111,300.00. Following the completion of the sale, the chief executive officer directly owned 333,576 shares of the company’s stock, valued at approximately $3,712,700.88. This represents a 2.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Replimune Group Trading Down 0.8%

REPL traded down $0.08 during mid-day trading on Friday, reaching $10.45. The stock had a trading volume of 67,479 shares, compared to its average volume of 4,261,384. The stock has a market capitalization of $819.70 million, a P/E ratio of -3.04 and a beta of 0.66. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.31 and a current ratio of 6.31. The firm’s fifty day simple moving average is $7.75 and its two-hundred day simple moving average is $7.56. Replimune Group, Inc. has a 52 week low of $2.68 and a 52 week high of $14.80.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). On average, equities analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current year.

Institutional Trading of Replimune Group

Several hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. lifted its holdings in Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after acquiring an additional 7,569 shares in the last quarter. US Bancorp DE increased its holdings in shares of Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company’s stock worth $45,000 after acquiring an additional 3,921 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Replimune Group by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after purchasing an additional 6,873 shares during the period. Raymond James Financial Inc. bought a new position in shares of Replimune Group during the 2nd quarter valued at about $69,000. Finally, GSA Capital Partners LLP bought a new position in shares of Replimune Group during the 3rd quarter valued at about $81,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on REPL shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Replimune Group in a research report on Monday, November 24th. JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price for the company in a report on Monday, October 20th. Leerink Partnrs raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $18.00 in a research report on Monday, October 20th. Finally, HC Wainwright upgraded Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Replimune Group presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.75.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.